SIBN vs. EMBC, TMCI, ATRI, IRMD, OFIX, SILK, KIDS, SRDX, OSUR, and NVRO
Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Embecta (EMBC), Treace Medical Concepts (TMCI), Atrion (ATRI), Iradimed (IRMD), Orthofix Medical (OFIX), Silk Road Medical (SILK), OrthoPediatrics (KIDS), Surmodics (SRDX), OraSure Technologies (OSUR), and Nevro (NVRO). These companies are all part of the "surgical & medical instruments" industry.
Embecta (NASDAQ:EMBC) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
Embecta presently has a consensus price target of $13.00, indicating a potential downside of 8.96%. SI-BONE has a consensus price target of $27.29, indicating a potential upside of 81.18%. Given Embecta's stronger consensus rating and higher possible upside, analysts clearly believe SI-BONE is more favorable than Embecta.
SI-BONE received 160 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 67.23% of users gave SI-BONE an outperform vote while only 0.00% of users gave Embecta an outperform vote.
In the previous week, SI-BONE had 8 more articles in the media than Embecta. MarketBeat recorded 25 mentions for SI-BONE and 17 mentions for Embecta. Embecta's average media sentiment score of 0.49 beat SI-BONE's score of 0.41 indicating that SI-BONE is being referred to more favorably in the news media.
Embecta has a net margin of 6.20% compared to Embecta's net margin of -29.93%. SI-BONE's return on equity of -18.42% beat Embecta's return on equity.
Embecta has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
93.8% of Embecta shares are held by institutional investors. Comparatively, 98.1% of SI-BONE shares are held by institutional investors. 0.3% of Embecta shares are held by company insiders. Comparatively, 5.4% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Embecta has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Summary
SI-BONE beats Embecta on 11 of the 18 factors compared between the two stocks.
Get SI-BONE News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
